Gregory A. Sgueglia, Giuseppe Tarantini and Giampaolo Niccoli Pages 458 - 462 ( 5 )
Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding. In a subanalysis of the PLATO trial focusing on patients with ST-elevation myocardial infarction, ticagrelor results were consistent with those of the overall trial. Additionally, possible pleiotropic effects of ticagrelor, including an appealing interaction with adenosine, might constitute a specific advantage in this particular subset of patients
Ticagrelor, ST-elevation myocardial infarction, PLATO, P2Y12 receptor, clopidogrel, platelet aggregation, acute coronary syndrome, thrombolysis, percutaneous coronary intervention, thienopyridine
UOC Emodinamica e Cardiologia Interventistica, Ospedale Santa Maria Goretti, Via Canova, 3, 04100 Latina, Italy.